CEO Cancer Gold Standard: Four organizations receive accreditation

The American Cancer Society’s Mid-South Division, LiDestri Foods, MDU Resources Group, Inc. and WCA Hospital have received CEO Cancer Gold Standard accreditation, recognizing the commitment of these organizations to taking concrete actions to reduce the cancer risk of employees and their families through screenings, early detection, and healthy changes in lifestyle.

“do something bold and venturesome about cancer within your own corporate families.”

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, more than one million employees and family members are benefiting from the vision and leadership of employers who have chosen to become Gold Standard accredited.

“We are pleased to recognize the efforts of these organizations in the fight against cancer, starting with improving the health and wellness of their own employees,” said Weldon. “I hope the commitment demonstrated by these organizations will encourage other employers, large and small, to become Gold Standard accredited.”

The CEO Cancer Gold Standard calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.

Other organizations joining the American Cancer Society’s Mid-South Division, LiDestri Foods, MDU Resources (NYSE: MDU) and WCA Hospital in championing this workplace-based effort to eliminate cancer as a public health threat include: Aetna (NYSE: AET), Aldagen, the American Cancer Society’s National Home Office, the American Legacy Foundation, the American Society of Clincial Oncology, Aptuit, AstraZeneca (NYSE: AZN), C-Change, CIGNA (NYSE: CI), Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals (NASDAQ:ENZN), Fox Chase Cancer Center, GlaxoSmithKline (NYSE: GSK), Hogan & Hartson, Independence Blue Cross & Blue Shield, Jenner & Block, Johnson & Johnson (NYSE: JNJ), The Lance Armstrong Foundation, M. D. Anderson Cancer Center, Millennium: The Takeda Oncology Company, Meridian Health, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute, Novartis (NYSE: NVS), The Oncology Nursing Society, OSI Pharmaceuticals (NASDAQ: OSIP), Pfizer (NYSE: PFE), PhRMA, PPD (NASDAQ: PPDI), Pride, Inc., Quintiles Transnational, sanofi-aventis (NYSE: SNY), SAS Institute, State Farm, The University of North Dakota, US Oncology, Valeant Pharmaceuticals (NYSE: VRX), Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.

SOURCE The CEO Roundtable on Cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care